A single purity percentage compresses a complex sample into one number. Two materials with similar reported purity can still contain different minor components, and those differences may matter to a sensitive research assay. The impurity profile deserves attention alongside the headline result.

FDA's specifications framework treats impurities as a distinct quality question. Its guidance is directed at drug development, but the underlying distinction helps researchers avoid confusing the amount of the main component with complete chemical characterization. FDA Q6A specifications and acceptance criteria

Consider the origin of a difference

Minor components can arise during production, storage or handling. An unexplained new signal may therefore be useful evidence of a change even when the overall reported purity looks similar. Identifying the cause requires appropriate analytical work rather than speculation from the shape of a trace.

Residual solvents are another separate consideration. FDA's ICH Q3C material organizes solvents by toxicological concern; it does not mean that a routine peptide purity method has measured them. The presence or absence of a dedicated result should remain explicit. FDA ICH Q3C solvent categories

Match the concern to the experiment

For exploratory research, the question is whether an uncharacterized component could confound the observed effect. That concern may be especially relevant when comparing batches or suppliers. A specialist can help decide whether additional characterization is proportionate and which method could resolve the issue.

An AXON evidence note should report what is known about the profile and what remains unassigned. It should not invent identities for unknown peaks or call a material safe merely because a nominal threshold was met. This article provides no supplier ranking, clinical safety claim or administration guidance. The quality decision belongs to the responsible scientific team.